Barclays analyst Saket Kalia raised the firm’s price target on Definitive Healthcare to $10 from $7 and keeps an Equal Weight rating on the shares. The updated price target reflects 18-times the company’s’ estimated fiscal 2024 EBITDA, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on DH:
- Definitive Healthcare price target lowered to $9 from $14 at Deutsche Bank
- Definitive Healthcare Corp. reports inducement grants under Nasdaq Listing Rule 5635(c)(4)
- Definitive Healthcare trading resumes
- Definitive Healthcare trading halted, volatility trading pause
- Definitive Healthcare reports Q3 EPS 9c, consensus 6c
